Corica, G.
Pirchio, R.
Milioto, A.
Nista, F.
Arecco, A.
Mattioli, L.
Auriemma, R. S.
Cocchiara, F.
Pivonello, R.
Colao, A.
Ferone, D.
Gatto, F. http://orcid.org/0000-0002-5062-9208
Article History
Received: 14 March 2023
Accepted: 24 August 2023
First Online: 11 September 2023
Declarations
:
: Diego Ferone has been a speaker for and participated on advisory boards and received research grants from Novartis AAA, Ipsen, Camurus and Recordati. Diego Ferone is a member of the Editorial Board of Journal of Endocrinological Investigation. Annamaria Colao received research grants from Novo Nordisk and Ipsen. Rosario Pivonello has been the Principal Investigator of Clinical and/or Translational Research Studies for Novartis, HRA Pharma, Ipsen, Shire, Corcept Therapeutics, Cortendo AB, Janssen Cilag, Camurus, Strongbridge, and Pfizer; Co-investigator of Research Studies for Pfizer; received research grants from Novartis, Pfizer, Ipsen, HRA Pharma, Shire, IBSA, Strongbridge Biopharma; has been an occasional consultant for Novartis, Ipsen, Pfizer, Shire, HRA Pharma, Cortendo AB, Ferring, Strongbridge Biopharma, Recordati, Corcept Therapeutics, Crinetics Pharmaceuticals, ARH Healthcare, Biohealth Italia; and has received fees and honoraria for presentations from Novartis, Shire, Pfizer and Recordati beyond the confines of this work. The other Authors have no conflicts of interest to declare.
: All procedures performed in the study were in accordance with the ethical standards of the Institutional ethical committees and with the 1964 Helsinki declarations and its later amendments.
: Informed consent was obtained from all individual participants included in the study.